OFFICIAL INACTION: A Science investigation shows that FDA oversight of clinical trials is lax, slow moving, and secretive—and that enforcement is declining.
Science | 1 Oct 2020 This story was supported by the Science Fund for Investigative Reporting. Please help Science pursue ambitious journalism projects. For nearly a decade, the Food and Drug Administration (FDA) cited osteopath Michael Harris for egregious errors in clinical trials he was overseeing. Agency inspectors found a litany of problems at Harris’s private firm, Aspen Clinical Research in…